SCY-770 Phase is a Scynexis Inc program in autosomal dominant polycystic kidney disease (ADPKD). Its next catalyst is a Readout in Q4 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Autosomal dominant polycystic kidney disease (ADPKD). Sponsor: Scynexis Inc (SCYX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for SCY-770 Phase is a Readout in Q4 2027.
No FDA decision for SCY-770 Phase is in our archive yet.
In our records SCY-770 Phase is under review or in development for Autosomal dominant polycystic kidney disease (ADPKD).
Scynexis Inc (SCYX).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.